Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-04-08

Clinical Trial Update: Ropivacaine Use in Femoral Nerve Block; What is the Minimal Effective Analgesic Concentration (MEAC 90) [Phase 4]

View source ↗

Summary

A Phase 4 trial update investigating the minimal effective analgesic concentration (MEAC 90) of ropivacaine for femoral nerve block in postoperative pain.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ropivacaine (Ropivacaine)

Snippet

Sponsor: Healthpoint Hospital | Conditions: Postoperative Pain | Phase 4 | Status: UNKNOWN